Soligenix (SNGX) Total Liabilities (2010 - 2026)
Soligenix's (SNGX) quarterly Total Liabilities came in at $3.8 million in Q1 2026, little changed YoY from $3.8 million in Q1 2025, and down 2.81% on a QoQ basis from $3.9 million in Q4 2025.
Soligenix (SNGX) Total Liabilities (2010 - 2026) Analysis & Trends
Soligenix (SNGX) has 17 years of Total Liabilities data on file, last reported at $3.8 million in Q1 2026.
- Quarterly Total Liabilities changed 0.4% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (changed 0.4% YoY) and the FY2025 annual result came in at $3.9 million, down 18.67% from the prior year.
- Total Liabilities fell to $3.8 million in Q1 2026, from $3.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $17.1 million in Q2 2022 to a low of $3.7 million in Q3 2025.
- A 5-year average of $8.7 million and a median of $7.1 million in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities rose 22.07% — and 2023, when it slumped 58.13%.
- Tracing SNGX's Total Liabilities over 5 years: stood at $16.8 million in 2022, then plunged by 56.57% to $7.3 million in 2023, then plunged by 33.35% to $4.8 million in 2024, then decreased by 18.67% to $3.9 million in 2025, then fell by 2.81% to $3.8 million in 2026.
- The last three Total Liabilities figures came in at $3.8 million (Q1 2026), $3.9 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 10.03 Bn |
| 10 | Soligenix | 6.34 Mn | 6.34 Mn | - | 3.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.85 Mn |
| Mar 31, 2026 | 3.83 Mn |
| Dec 31, 2025 | 3.94 Mn |
| Sep 30, 2025 | 3.70 Mn |
| Jun 30, 2025 | 3.93 Mn |
| Mar 31, 2025 | 3.85 Mn |
| Dec 31, 2024 | 4.85 Mn |
| Sep 30, 2024 | 4.54 Mn |
| Jun 30, 2024 | 6.40 Mn |
| Mar 31, 2024 | 7.29 Mn |
| Dec 31, 2023 | 7.27 Mn |
| Sep 30, 2023 | 7.08 Mn |
| Jun 30, 2023 | 8.03 Mn |
| Mar 31, 2023 | 14.49 Mn |
| Dec 31, 2022 | 16.75 Mn |
| Sep 30, 2022 | 16.92 Mn |
| Jun 30, 2022 | 17.11 Mn |
| Mar 31, 2022 | 17.09 Mn |
| Dec 31, 2021 | 16.15 Mn |
| Sep 30, 2021 | 14.66 Mn |